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Background
High-throughput sequencing technology challenges the
traditional histopathological classification of cancer, and
proposes new taxonomies derived from global transcrip-
tional patterns. They provided in-depth of new informa-
tion that can reframe our understanding of human
cancer biology. The novel observations that cancer phe-
notype characterized by immune effectors mechanisms
are commonly observed during acute inflammation reac-
tion. Several studies revealed associations between
inflammatory status and a favorable natural history of
the disease or a better responsiveness to cancer immune
therapy. In the present study we applied RNA-seq analy-
sis of 15 melanoma cells line, extensively classified
(genetically, functionally and clinically) to explore the
association between their constitutive pSTAT1 activa-
tion and the constitutive expression of genes associated
with the regulation of the JAK/STAT pathway. With
high resolution of sequencing information, we also
attempt to identify the genetic determinants responsible
for the phenotype (IRF-1, STAT1, Th1) associated with
good prognosis and responsiveness to immunotherapy.
Method
Rna-seq was performed using Solexa (Illumina GAII
technology). CLC-bio workbench and deFuse algorithm
were used for the alignment and for gene fusion analysis
respectively.
Results
Information about gene expression levels, splicing variants
and fused gene were obtained. Novel fusion genes and
mutations which could not be identified by conventional
expression analysis were identified. Consistent tumor het-
erogeneity was observed across all 15 samples.
Conclusion
Next generation sequencing technologies provides a
more comprehensive view of cancer mutational land-
scapes and hereby a better understanding of their patho-
genesis. This could be an open interesting perspective
for new treatment approaches and clinical trial designs.
Authors’ details
1Infectious Disease and Immunogenetics Section (IDIS), Department of
Transfusion Medicine, Clinical Center, Trans-NIH Center for Human
Immunology (CHI), National Institutes of Health, Bethesda, MD, USA.
2Biometric Research Branch, Division of cancer treatment and diagnosis,
National Institutes of Health, Rockville, MD, USA. 3Surgery Branch, NCI,
National Institutes of Health, Bethesda, MD, USA. 4Weill Cornell Medical
College in Qatar, Doha, Qatar. 5Sidra Medical and Research Center, Doha,
Qatar.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P141
Cite this article as: De Giorgi et al.: NGS technology applied to
melanoma cell lines. Journal for ImmunoTherapy of Cancer 2013 1(Suppl
1):P141.
1Infectious Disease and Immunogenetics Section (IDIS), Department of
Transfusion Medicine, Clinical Center, Trans-NIH Center for Human
Immunology (CHI), National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article
De Giorgi et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P141
http://www.immunotherapyofcancer.org/content/1/S1/P141
© 2013 De Giorgi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
